• Something wrong with this record ?

The safety of neoadjuvant hormonal treatment in infants with cryptorchidism

V. Fiala, Z. Jiraskova, M. Drlik, J. Sedlacek, Z. Dite, P. Novakova, R. Kocvara, M. Kalousova, V. Soukup

. 2022 ; 18 (6) : 846.e1-846.e6. [pub] 20220519

Language English Country England, Great Britain

Document type Journal Article, Randomized Controlled Trial

BACKGROUND/PURPOSE: The standard treatment for boys with non-syndromic cryptorchidism is an early orchidopexy. It is unclear if surgical intervention alone is enough for future fertility. Recent studies show benefit of neoadjuvant or adjuvant hormonal treatment with gonadorelin (GnRH) for spermatogonia maturation based on testicular biopsy. The aim of this prospective study was to assess the safety of this treatment in infants with undescended testis at the recommended timing of early gonadorelin administration and timing of orchidopexy. METHODS: Unilateral cryptorchid full term boys were initially examined (including hormonal, physical and ultrasound examination) at the age of 2.5-3.5 months. At 6 months of age, cryptorchidism was confirmed. Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment. Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups). The following orchidopexy was performed before 12 months of age with repeated examination at time of surgery. Penile size and testicular volume (using ultrasound) and basal serum levels of LH, FSH, testosterone, Inhibin B and AMH were recorded at age of 3.0 (mean) months and 11.0 (mean) months (date of surgery). The stimulation hormonal levels were checked during GnRH administration. RESULTS: Between minipuberty (mean 3 months) and time of orchidopexy (mean 11 months of age) the penile size increased significantly and similarly in both groups. There was no significant difference in the change of the volume of descended testis between the groups nor of the volume of undescended testis. In addition, we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a) CONCLUSION: The neoadjuvant gonadorelin stimulation in infants with unilateral undescended testis has not shown any specific effect on the development of penile size, testicular volume and hormonal levels at time of orchidopexy in comparison with boys without stimulation, and in the mid-term, this treatment can be considered safe. Further follow-up is necessary to evaluate the long-term effect of this early treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032506
003      
CZ-PrNML
005      
20230131151521.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpurol.2022.05.010 $2 doi
035    __
$a (PubMed)35691791
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Fiala, Vojtech $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: vojtech.fiala@vfn.cz
245    14
$a The safety of neoadjuvant hormonal treatment in infants with cryptorchidism / $c V. Fiala, Z. Jiraskova, M. Drlik, J. Sedlacek, Z. Dite, P. Novakova, R. Kocvara, M. Kalousova, V. Soukup
520    9_
$a BACKGROUND/PURPOSE: The standard treatment for boys with non-syndromic cryptorchidism is an early orchidopexy. It is unclear if surgical intervention alone is enough for future fertility. Recent studies show benefit of neoadjuvant or adjuvant hormonal treatment with gonadorelin (GnRH) for spermatogonia maturation based on testicular biopsy. The aim of this prospective study was to assess the safety of this treatment in infants with undescended testis at the recommended timing of early gonadorelin administration and timing of orchidopexy. METHODS: Unilateral cryptorchid full term boys were initially examined (including hormonal, physical and ultrasound examination) at the age of 2.5-3.5 months. At 6 months of age, cryptorchidism was confirmed. Those with non-syndromic cryptorchidism and palpable or sonographically detected testis were randomly assigned into two groups: with and without intranasal gonadorelin treatment. Inclusion criteria were met by 36 boys (21 in GNRH and 15 in the control groups). The following orchidopexy was performed before 12 months of age with repeated examination at time of surgery. Penile size and testicular volume (using ultrasound) and basal serum levels of LH, FSH, testosterone, Inhibin B and AMH were recorded at age of 3.0 (mean) months and 11.0 (mean) months (date of surgery). The stimulation hormonal levels were checked during GnRH administration. RESULTS: Between minipuberty (mean 3 months) and time of orchidopexy (mean 11 months of age) the penile size increased significantly and similarly in both groups. There was no significant difference in the change of the volume of descended testis between the groups nor of the volume of undescended testis. In addition, we did not find any significant difference in the change (drop) of hormonal levels of LH, FSH, Testosterone, Inhibin B and AMH (Table 1a) CONCLUSION: The neoadjuvant gonadorelin stimulation in infants with unilateral undescended testis has not shown any specific effect on the development of penile size, testicular volume and hormonal levels at time of orchidopexy in comparison with boys without stimulation, and in the mid-term, this treatment can be considered safe. Further follow-up is necessary to evaluate the long-term effect of this early treatment.
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    12
$a kryptorchismus $x farmakoterapie $x chirurgie $7 D003456
650    _2
$a folikuly stimulující hormon $7 D005640
650    _2
$a hormon uvolňující gonadotropiny $7 D007987
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a prospektivní studie $7 D011446
650    _2
$a testis $x diagnostické zobrazování $x chirurgie $x patologie $7 D013737
650    _2
$a testosteron $7 D013739
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Jiraskova, Zuzana $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: valova.z@gmail.com
700    1_
$a Drlik, Marcel $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: marcel.drlik@vfn.cz
700    1_
$a Sedlacek, Josef $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: josef.sedlacek@vfn.cz
700    1_
$a Dite, Zdenek $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: zdenek.dite@vfn.cz
700    1_
$a Novakova, Petra $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: petra.novakova2@vfn.cz
700    1_
$a Kocvara, Radim $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: radim.kocvara@vfn.cz
700    1_
$a Kalousova, Marta $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: marta.kalousova@lf1.cuni.cz
700    1_
$a Soukup, Viktor $u Department of Urology, General University Hospital and 1st. Faculty of Medicine of Charles University in Prague, Czech Republic. Electronic address: viktor.soukup@vfn.cz
773    0_
$w MED00166989 $t Journal of pediatric urology $x 1873-4898 $g Roč. 18, č. 6 (2022), s. 846.e1-846.e6
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35691791 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151517 $b ABA008
999    __
$a ok $b bmc $g 1891330 $s 1183841
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 18 $c 6 $d 846.e1-846.e6 $e 20220519 $i 1873-4898 $m Journal of pediatric urology $n J Pediatr Urol $x MED00166989
LZP    __
$a Pubmed-20230120

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...